Starling Oncology (STLNW) Change in Inventory (2021 - 2026)

Starling Oncology (STLNW) has reported Change in Inventory for 6 consecutive years, with -$4.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Inventory fell 223.03% year-over-year to -$4.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.2 million (down 5.35% YoY), and the FY2025 full-year result was $6.8 million, up 287.85% from the prior year.
• Change in Inventory fell to -$4.3 million in Q2 2026 per STLNW's latest filing, from $7.4 million in the prior quarter.
• Across five years, Change in Inventory topped out at $7.4 million in Q1 2026 and bottomed at -$4.3 million in Q2 2026.
• Historically, Change in Inventory has averaged $691666.7 across 5 years, with a median of $626000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Inventory jumped 13420.0% in 2022, then slumped 20366.67% in 2024.
• Over 5 years, Change in Inventory stood at -$852000.0 in 2022, then soared by 272.77% to $1.5 million in 2023, then slumped by 104.55% to -$67000.0 in 2024, then slumped by 2895.52% to -$2.0 million in 2025, then sank by 113.2% to -$4.3 million in 2026.
• According to Business Quant data, Change in Inventory over the past three periods registered -$4.3 million, $7.4 million, and -$2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.